Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis

Conclusion: The meta-analysis demonstrates that infliximab alone is a well-tolerated and effective treatment for IVIG-resistant KD. The additional efficacy of infliximab to IVIG for initial treatment of KD is limited. More large and high-quality trials are needed to confirm the efficacy of infliximab, especially for intensification of primary treatment for KD.What is Known:• Infliximab is a novel monoclonal antibody specifically blocking tumor necrosis factor-alpha and is approved for treatment of several immune-mediated inflammatory disorders.• The efficacy of infliximab in treating children with Kawasaki disease is controversial.What is New:• Infliximab is an effective and safe treatment for children with refractory Kawasaki disease but adds limited efficacy to intravenous immunoglobulin for initial treatment of Kawasaki disease.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research